Akèy › Limfom Selil-T › Michigan
Etid klinik pou Limfom Selil-T nan Michigan
5 etid pou Limfom Selil-T ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
Tèks ofisyèl etid la (Anglè)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Roger Cancer Center University of Michigan Health, Ann Arbor
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Wayne State University/Karmanos Cancer Institute, Detroit
- Weisberg Cancer Treatment Center, Farmington Hills
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06724237Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- University of Michigan, Ann Arbor
- Barbara Ann Karmanos Cancer Institute Wayne State University, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2025 · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- C.S. Mott Children's Hospital, Ann Arbor
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.